More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
The event was the sixth Workshop on Medical Applications of Spectroscopic X-ray Detectors, which wrapped Sept. 1 at the largest particle physics lab in the world.
The effect shows up on functional MRI as increased brain activity in regions involved in pain, emotion and attention—not only during the procedure but also afterward, when patients remember the experience and score its discomfort level.
Six radiologists interpreting around 500 chest radiographs with an assist from AI bested unaided radiologists in measures of efficiency and/or accuracy in a new comparative performance study.
New research, published in JAMA Cardiology, challenges the common belief that AFib is more likely to develop among men than women. The key problem, it seems, is that prior research teams did not understand the significance of certain risk factors.
Two branch chiefs with the cancer imaging program at NIH’s National Cancer Institute have produced a written commemoration to mark the golden anniversary of 1971’s National Cancer Act.
